From first toxicology study to IND submission in as little as 9 months – driven by optimized timelines, parallelized workflows, and proactive risk management.
Subject matter experts tailor study designs to your asset type – whether small molecules, biologics, or emerging modalities – ensuring fit-for-purpose strategies from the outset.
Your program is led by DABT-certified toxicologists and histopathology experts, providing deep mechanistic insight and regulatory foresight.
An aligned toxicology, ADME, pharmacology, and independent QAU team operating across India and the USA troubleshoots issues rapidly and strengthens your IND package in real time.
Our LC-MS/MS and broad bioanalytical platform delivers reliable quantification in complex matrices, evaluating exposure and toxicokinetic data for regulators.
Benefit from centrally managed large animal programs with access to premier facilities in the US, Europe, and Asia, all coordinated through a single accountable partner.
A dedicated Chief Scientific Officer, experienced program leaders, and proactive project managers guide your asset seamlessly from discovery through IND and beyond.
Our global supply chain and logistics management keep your studies on schedule with seamless movement of test articles and samples across regions for US and EU submissions.
Aragen’s experts support IND-enabling pharmacology, toxicology, metabolism, and manufacturing. We customize programs based on your drug type and objectives, ensuring a streamlined process from candidate selection to regulatory alignment for faster clinical trials and on-time success.
With 30+ years of experience, we offer:
